Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Substitution of Subcutaneous Abatacept for Belatacept in Kidney Transplantation
NCT05975450Phase 1Completed
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abatacept in kidney transplant rejection. Primary endpoints: Number of Participants Who Are Compliant With Self-administration at 12 months, Number of Participants Who Remain Free of Biopsy-proven Acute T-cell Mediated Rejection (aTCMR) or Antibody-mediated Rejection (ABMR) at 12 months and 5 more. Started Aug 2023; status: completed.
02
Drugs
abatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT05975450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05975450.